Current Month 2005
Article Features
  Breast Cancer-Causing Gene May Indicate Survival
Studying Biomarkers to Predict Patient Response to Cancer Treatment
Increasing Incidence BRCA2 Mutations in Icelandic Study
New Cellular Flaw Found in Some Virulent Breast Cancers
Study Links Dairy Products to Moderate Breast Cancer Risk Reduction
File Compression Can Expand Mammography’s Power
Fatigue and Breast Cancer Survivors
Family Influences Cancer Treatment Among Older Hispanics
Immune Substances May Help Antibody-Based Drugs Fight Cancer
Artificial Light Stimulates Breast Cancer Growth in Laboratory Mice
Differences in Management of Older Women Influences Breast Cancer Survival
Protein Fragment May Help Predict Breast Cancer Progression
Global Signaling Study Suggests Cancer Link to Protein Promiscuity
Optimal Adjuvant Radiation Therapy Associated with Improved Survival
Permanent Radiation Seed Implants As an Option for Breast Cancer Patients
Radiotherapy after Lumpectomy Saves Lives
Sex Hormones Not a Useful Predictor of Breast Cancer Risk
Soy Phytoestrogens May Block Estrogen Effects
Faults in Newly Discovered Breast Stem Cells May Lead to Tumors
Research Adds to Concerns About Surgeons Performing Occasional Breast Cancer Operations
Tumor Cells that Border Normal Tissue are the Most Dangerous


New Clinical Data Show Benefits of Femara(R) for Women with Breast Cancer Even After Prolonged Period of No Anti-Cancer Treatment

Women with hormone-sensitive early breast cancer who switched to Femara(R) (letrozole tablets) from placebo as part of a landmark trial experienced significant improvements in overall survival, disease-free survival and distant metastases, according to data presented at the 28th annual San Antonio Breast Cancer Symposium in Texas.

The analysis represents the first time that an aromatase inhibitor has demonstrated a benefit in starting therapy up to five years after the end of a patient taking tamoxifen, another medicine used in the treatment of hormone-related breast cancers.

In this new analysis of the landmark MA-17 trial, postmenopausal women who switched from placebo to Femara experienced a 69 percent reduction in the risk that their breast cancer would return (recurrence). There also was a 72 percent reduction in the risk that the cancer would spread to a distant part of the body (metastasis). A 47 percent reduction in the risk of dying from their disease was also observed. These observations must be confirmed by additional analysis and longer-term follow-up.

MA-17 is a Phase III, international, double-blinded, randomized, multi-center trial. It is coordinated by the National Cancer Institute of Canada Clinical Trials Group at Queens University in Kingston, Ontario, Canada with funding from the Canadian Cancer Society and supported by Novartis.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon